Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

Recruiting now

Conditions studied: Invasive Aspergillosis

In brief

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.

Key facts

Study ID

NCT06069505

Run by

Bart Rijnders

People needed

300

Starts

2017-07-01

Expected to finish

2030-12-31

Last updated by the study team

2024-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older.
• Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.
• A bronchoalveolar lavage is planned or has been performed <48hrs earlier

You may not qualify if…

• Patients unable or unwilling to provide consent

Where it is running

• Erasmus Medical Center (EMC) — Rotterdam, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.